Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

Retrieval of chronic hepatitis C patients. A manifesto for action to eliminate hepatitis C in the Netherlands: the CELINE project.

van Dijk M, Kracht PAM, Arends JE, Blokzijl H, Burger DM, van Erpecum KJ, van Hoek B, de Knegt RJ, Posthouwer D, Ramsoekh D, Rijnders BJA, Schinkel J, Willemse SB, van der Valk M, Drenth JPH, Behalf Of The HepNed Study Group O.

Neth J Med. 2019 May;77(4):131-138.

2.

Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis.

Willemse S, Smit C, Sogni P, Sarcletti M, Uberti-Foppa C, Wittkop L, Raben D, D'Arminio Monforte A, Dabis F, Van Der Valk M; Hepatocellular Carcinoma Screening Project Working Group for the Collaboration of Observational HIV on behalf of Epidemiological Research Europe (COHERE) In EuroCoord.

J Viral Hepat. 2019 May 28. doi: 10.1111/jvh.13146. [Epub ahead of print] No abstract available.

PMID:
31136059
3.

Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIV.

van Zoest RA, Law M, Sabin CA, Vaartjes I, van der Valk M, Arends JE, Reiss P, Wit FW.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):562-571. doi: 10.1097/QAI.0000000000002069.

PMID:
31045648
4.

Complete response after neoadjuvant treatment for rectal cancer - Authors' reply.

van der Valk MJM, Hilling DE, Beets GL; investigators.

Lancet. 2019 Apr 27;393(10182):1694-1695. doi: 10.1016/S0140-6736(18)33178-7. No abstract available.

PMID:
31034371
5.

Plaster, splint, brace, tape or functional mobilization after first-time patellar dislocation: what's the evidence?

Vermeulen D, van der Valk MR, Kaas L.

EFORT Open Rev. 2019 Mar 27;4(3):110-114. doi: 10.1302/2058-5241.4.180016. eCollection 2019 Mar. Review.

6.

Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies.

Wandeler G, Mauron E, Atkinson A, Dufour JF, Kraus D, Reiss P, Peters L, Dabis F, Fehr J, Bernasconi E, van der Valk M, Smit C, Gjærde LK, Rockstroh J, Neau D, Bonnet F, Rauch A; Swiss HIV Cohort Study, Athena Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort.

J Hepatol. 2019 Aug;71(2):274-280. doi: 10.1016/j.jhep.2019.03.032. Epub 2019 Apr 6.

PMID:
30965070
7.

HIV-1 exposure and immune activation enhance sexual transmission of Hepatitis C virus by primary Langerhans cells.

Nijmeijer BM, Sarrami-Forooshani R, Steba GS, Schreurs RR, Koekkoek SM, Molenkamp R, Schinkel J, Reiss P, Siegenbeek van Heukelom ML, van der Valk M, Ribeiro CM, Geijtenbeek TB.

J Int AIDS Soc. 2019 Mar;22(3):e25268. doi: 10.1002/jia2.25268.

8.

Synovial chondromatosis of the hip, a case report and literature review.

van der Valk MR, Veltman ES, Assink J, Veen MR.

J Orthop. 2019 Feb 28;16(3):249-253. doi: 10.1016/j.jor.2019.02.010. eCollection 2019 May-Jun. Review.

PMID:
30923422
9.

Quality of Life After Curative Resection for Rectal Cancer in Patients Treated With Adjuvant Chemotherapy Compared With Observation: Results of the Randomized Phase III SCRIPT Trial.

van der Valk MJM, Hilling DE, Meershoek-Klein Kranenbarg E, Peeters KCMJ, Kapiteijn E, Tsonaka R, van de Velde CJH, Marang-van de Mheen PJ.

Dis Colon Rectum. 2019 Jun;62(6):711-720. doi: 10.1097/DCR.0000000000001336.

PMID:
30870225
10.

The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals.

Popping S, Bade D, Boucher C, van der Valk M, El-Sayed M, Sigurour O, Sypsa V, Morgan T, Gamkrelidze A, Mukabatsinda C, Deuffic-Burban S, Ninburg M, Feld J, Hellard M, Ward J.

J Virus Erad. 2019 Jan 1;5(1):60-66.

11.

Disqualification of Neoadjuvant Rectal Score Based on Data of 6596 Patients From the Netherlands Cancer Registry.

van der Valk MJM, Vuijk FA, Putter H, van de Velde CJH, Beets GL, Hilling DE.

Clin Colorectal Cancer. 2019 Jun;18(2):e231-e236. doi: 10.1016/j.clcc.2019.01.001. Epub 2019 Jan 19.

PMID:
30772135
12.

ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation.

Durmus S, van der Valk M, Teunissen SF, Song JY, Wagenaar E, Beijnen JH, Schinkel AH.

Arch Toxicol. 2019 Mar;93(3):775-790. doi: 10.1007/s00204-019-02394-w. Epub 2019 Jan 30.

PMID:
30701287
13.

Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM.

Newsum AM, Kooij KW, Boyd A, Smit C, Wit FWNM, van der Meer JTM, Prins M, Reiss P, van der Valk M; MOSAIC study group, ATHENA observational HIV cohort and NVHB-SHM hepatitis working group.

AIDS. 2019 Apr 1;33(5):833-844. doi: 10.1097/QAD.0000000000002138.

PMID:
30649050
14.

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).

Boerekamps A, Vanwolleghem T, van der Valk M, van den Berk GE, van Kasteren M, Posthouwer D, Dofferhoff ASM, van Hoek B, Ramsoekh D, Koopsen J, Schinkel J, Florence E, Arends JE, Rijnders BJ.

J Hepatol. 2019 Mar;70(3):554-557. doi: 10.1016/j.jhep.2018.10.032. Epub 2018 Dec 5. No abstract available.

PMID:
30527953
15.

Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer.

Claassen YH, van der Valk MJ, Breugom AJ, Frouws MA, Bastiaannet E, Liefers GJ, van de Velde CJ, Kapiteijn E.

Cochrane Database Syst Rev. 2018 Nov 21;11:CD012326. doi: 10.1002/14651858.CD012326.pub2.

PMID:
30480771
16.

Staging laparoscopy with ultrasound and near-infrared fluorescence imaging to detect occult metastases of pancreatic and periampullary cancer.

Handgraaf HJM, Sibinga Mulder BG, Shahbazi Feshtali S, Boogerd LSF, van der Valk MJM, Fariña Sarasqueta A, Swijnenburg RJ, Bonsing BA, Vahrmeijer AL, Mieog JSD.

PLoS One. 2018 Nov 1;13(11):e0205960. doi: 10.1371/journal.pone.0205960. eCollection 2018.

17.

Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV/HCV-coinfected MSM with risk of onward transmission.

Newsum AM, Molenkamp R, van der Meer JT, Rebers SP, Prins M, van der Valk M, Schinkel J.

J Hepatol. 2018 Oct;69(4):968-970. doi: 10.1016/j.jhep.2018.06.021. Epub 2018 Jul 4. No abstract available.

PMID:
30227918
18.

[The older HIV patient in the Netherlands].

Verheij E, van Zoest RA, van der Valk M, Wit FW, Reiss P.

Ned Tijdschr Geneeskd. 2018 Jul 5;162. pii: D2886. Dutch.

PMID:
30040311
19.

[Intraoperative imaging using fluorescence, 5 years later].

van der Valk MJM, Handgraaf HJM, Sibinga-Mulder BG, Hilling DE, van Dam GM, Vahrmeijer AL.

Ned Tijdschr Geneeskd. 2018 Jun 21;162. pii: D2067. Dutch.

PMID:
30040255
20.

High proportions of liver fibrosis and cirrhosis in an ageing population of people who use drugs in Amsterdam, The Netherlands.

van Santen DK, Schim van der Loeff MF, Cartier van Dissel J, Martens JPD, van der Valk M, Prins M.

Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1168-1176. doi: 10.1097/MEG.0000000000001213.

PMID:
30028776
21.

Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.

van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, Habr-Gama A, Perez RO, Renehan AG, van de Velde CJH; IWWD Consortium.

Lancet. 2018 Jun 23;391(10139):2537-2545. doi: 10.1016/S0140-6736(18)31078-X.

PMID:
29976470
22.

Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies.

Severs M, Spekhorst LM, Mangen MJ, Dijkstra G, Löwenberg M, Hoentjen F, van der Meulen-de Jong AE, Pierik M, Ponsioen CY, Bouma G, van der Woude JC, van der Valk ME, Romberg-Camps MJL, Clemens CHM, van de Meeberg P, Mahmmod N, Jansen J, Jharap B, Weersma RK, Oldenburg B, Festen EAM, Fidder HH.

Inflamm Bowel Dis. 2018 May 18;24(6):1298-1306. doi: 10.1093/ibd/izy004.

PMID:
29688413
23.

Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.

Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME.

J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25051. doi: 10.1002/jia2.25051.

24.

Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy.

Boogerd LS, van der Valk MJ, Boonstra MC, Prevoo HA, Hilling DE, van de Velde CJ, Sier CF, Fariña Sarasqueta A, Vahrmeijer AL.

Onco Targets Ther. 2018 Mar 23;11:1655-1664. doi: 10.2147/OTT.S145473. eCollection 2018.

25.

Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study.

Boogerd LSF, Hoogstins CES, Schaap DP, Kusters M, Handgraaf HJM, van der Valk MJM, Hilling DE, Holman FA, Peeters KCMJ, Mieog JSD, van de Velde CJH, Farina-Sarasqueta A, van Lijnschoten I, Framery B, Pèlegrin A, Gutowski M, Nienhuijs SW, de Hingh IHJT, Nieuwenhuijzen GAP, Rutten HJT, Cailler F, Burggraaf J, Vahrmeijer AL.

Lancet Gastroenterol Hepatol. 2018 Mar;3(3):181-191. doi: 10.1016/S2468-1253(17)30395-3. Epub 2018 Jan 30.

PMID:
29361435
26.

Incisional Negative-Pressure Wound Therapy for Perineal Wounds After Abdominoperineal Resection for Rectal Cancer, a Pilot Study.

van der Valk MJM, de Graaf EJR, Doornebosch PG, Vermaas M.

Adv Wound Care (New Rochelle). 2017 Dec 1;6(12):425-429. doi: 10.1089/wound.2017.0749.

27.

Noncommunicable Diseases in People Living With HIV: Time for Integrated Care.

van der Valk M, Reiss P.

J Infect Dis. 2017 Dec 19;216(12):1481-1483. doi: 10.1093/infdis/jix525. No abstract available.

PMID:
29253145
28.

Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.

Smolders EJ, Smit C, de Kanter C, Dofferhoff A, Arends JE, Brinkman K, Rijnders B, van der Valk M, Reiss P, Burger DM; ATHENA National HIV Observational Cohort.

HIV Med. 2018 Mar;19(3):216-226. doi: 10.1111/hiv.12570. Epub 2017 Dec 1.

PMID:
29194939
29.

High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands.

Boerekamps A, Newsum AM, Smit C, Arends JE, Richter C, Reiss P, Rijnders BJA, Brinkman K, van der Valk M; NVHB-SHM Hepatitis Working Group and the Netherlands ATHENA HIV Observational Cohort.

Clin Infect Dis. 2018 Apr 17;66(9):1352-1359. doi: 10.1093/cid/cix1004.

PMID:
29186365
30.

Cardiovascular Disease Prevention Policy in Human Immunodeficiency Virus: Recommendations From a Modeling Study.

Smit M, van Zoest RA, Nichols BE, Vaartjes I, Smit C, van der Valk M, van Sighem A, Wit FW, Hallett TB, Reiss P; Netherlands AIDS Therapy Evaluation in The Netherlands (ATHENA) Observational HIV Cohort.

Clin Infect Dis. 2018 Feb 10;66(5):743-750. doi: 10.1093/cid/cix858.

31.

Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.

Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).

Lancet Gastroenterol Hepatol. 2018 Feb;3(2):125-133. doi: 10.1016/S2468-1253(17)30284-4. Epub 2017 Oct 3.

PMID:
28986139
32.

Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected Controls.

Kooij KW, Vogt L, Wit FWNM, van der Valk M, van Zoest RA, Goorhuis A, Prins M, Post FA, Reiss P; AGEhIV Cohort Study.

J Infect Dis. 2017 Sep 15;216(6):622-631. doi: 10.1093/infdis/jix202. Erratum in: J Infect Dis. 2018 Apr 23;217(10):1673.

PMID:
28934420
33.

Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients.

Smolders EJ, Smit C, T M M de Kanter C, Dofferiiof ASM, Arends JE, Brinkman K, Rijnders B, van der Valk M, Reiss P, Burger DM.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):193-199. doi: 10.1097/QAI.0000000000001488.

PMID:
28902678
34.

Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.

van Tilborg M, Lieveld FI, Smolders EJ, van Erpecum KJ, de Kanter CTMM, Maan R, van der Valk M, Arends JE, Dofferhoff ASM, Blokzijl H, Bijmolen M, Drenth JPH, de Knegt RJ, Burger DM; HepNed Study Group.

Aliment Pharmacol Ther. 2017 Nov;46(9):864-872. doi: 10.1111/apt.14288. Epub 2017 Sep 7.

35.

Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.

van der Ree MH, Stelma F, Willemse SB, Brown A, Swadling L, van der Valk M, Sinnige MJ, van Nuenen AC, de Vree JML, Klenerman P, Barnes E, Kootstra NA, Reesink HW.

Antiviral Res. 2017 Oct;146:139-145. doi: 10.1016/j.antiviral.2017.08.016. Epub 2017 Aug 24.

36.

Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease.

Severs M, Mangen MJ, Fidder HH, van der Valk ME, van der Have M, van Bodegraven AA, Clemens CHM, Dijkstra G, Jansen JM, de Jong DJ, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Pierik M, Ponsioen CY, Romberg-Camps MJL, Siersema PD, Jharap B, van der Woude JC, Zuithoff NPA, Oldenburg B.

Inflamm Bowel Dis. 2017 Sep;23(9):1568-1576. doi: 10.1097/MIB.0000000000001201.

PMID:
28700534
37.

Successful implementation of hepatitis C virus treatment in two large HIV clinics in Amsterdam: hepatitis C virus treatment cascade of care.

Saris J, van den Berk G, Moha DA, van der Meer J, Brinkman K, van der Valk M.

AIDS. 2017 Jul 31;31(12):1779-1780. doi: 10.1097/QAD.0000000000001566. No abstract available.

PMID:
28700397
38.

Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM).

Newsum AM, Stolte IG, van der Meer JT, Schinkel J, van der Valk M, Vanhommerig JW, Buvé A, Danta M, Hogewoning A, Prins M; MOSAIC collaborators.

Euro Surveill. 2017 May 25;22(21). pii: 30540. doi: 10.2807/1560-7917.ES.2017.22.21.30540.

39.

Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue.

Boogerd LSF, Vuijk FA, Hoogstins CES, Handgraaf HJM, van der Valk MJM, Kuppen PJK, Sier CFM, van de Velde CJH, Burggraaf J, Fariña-Sarasqueta A, Vahrmeijer AL.

Biomark Cancer. 2017 May 17;9:1179299X17710016. doi: 10.1177/1179299X17710016. eCollection 2017.

40.

Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy.

van Zoest RA, van der Valk M, Wit FW, Vaartjes I, Kooij KW, Hovius JW, Prins M, Reiss P; AGEhIV Cohort Study Group.

Eur J Prev Cardiol. 2017 Aug;24(12):1297-1307. doi: 10.1177/2047487317714350. Epub 2017 Jun 5.

41.

What is there to learn for watch-and-wait in rectal cancer?

van der Valk MJM, Hilling DE, van de Velde CJH.

Lancet Gastroenterol Hepatol. 2017 Jul;2(7):467-468. doi: 10.1016/S2468-1253(17)30081-X. Epub 2017 May 4. No abstract available.

PMID:
28479373
42.

[Twenty years of combination antiretroviral therapy for HIV infection in the Netherlands: progression and new challenges].

Brinkman K, Boender TS, van der Valk M, van Sighem A, Reiss P, Kroon FP.

Ned Tijdschr Geneeskd. 2017;161:D1123. Dutch.

PMID:
28443809
43.

Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101.

Stelma F, van der Ree MH, Sinnige MJ, Brown A, Swadling L, de Vree JML, Willemse SB, van der Valk M, Grint P, Neben S, Klenerman P, Barnes E, Kootstra NA, Reesink HW.

Hepatology. 2017 Jul;66(1):57-68. doi: 10.1002/hep.29148. Epub 2017 Jun 7.

44.

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.

van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J, van Nuenen AC, Beuers U, Hadi S, Harbers M, van der Veer E, Liu K, Grundy J, Patick AK, Pavlicek A, Blem J, Huang M, Grint P, Neben S, Gibson NW, Kootstra NA, Reesink HW.

Lancet. 2017 Feb 18;389(10070):709-717. doi: 10.1016/S0140-6736(16)31715-9. Epub 2017 Jan 11.

PMID:
28087069
45.

Characterization of Hepatitis C Virus (HCV) Envelope Diversification from Acute to Chronic Infection within a Sexually Transmitted HCV Cluster by Using Single-Molecule, Real-Time Sequencing.

Ho CKY, Raghwani J, Koekkoek S, Liang RH, Van der Meer JTM, Van Der Valk M, De Jong M, Pybus OG, Schinkel J, Molenkamp R.

J Virol. 2017 Feb 28;91(6). pii: e02262-16. doi: 10.1128/JVI.02262-16. Print 2017 Mar 15.

46.

Truncation of the MSH2 C-terminal 60 amino acids disrupts effective DNA mismatch repair and is causative for Lynch syndrome.

Wielders E, Delzenne-Goette E, Dekker R, van der Valk M, Te Riele H.

Fam Cancer. 2017 Apr;16(2):221-229. doi: 10.1007/s10689-016-9945-x.

PMID:
27873144
47.

Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.

Rockstroh JK, Ingiliz P, Petersen J, Peck-Radosavljevic M, Welzel TM, Van der Valk M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S.

Antivir Ther. 2017;22(3):225-236. doi: 10.3851/IMP3108. Epub 2016 Nov 15.

PMID:
27845298
48.

Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection.

van der Valk M, Zaaijer HL, Kater AP, Schinkel J.

J Hepatol. 2017 Jan;66(1):242-243. doi: 10.1016/j.jhep.2016.09.014. Epub 2016 Oct 1. No abstract available.

PMID:
27702641
49.

Cigarette Smoking and Inflammation, Monocyte Activation, and Coagulation in HIV-Infected Individuals Receiving Antiretroviral Therapy, Compared With Uninfected Individuals.

Kooij KW, Wit FW, Booiman T, van der Valk M, Schim van der Loeff MF, Kootstra NA, Reiss P; AGEhIV Cohort Study Group.

J Infect Dis. 2016 Dec 15;214(12):1817-1821. Epub 2016 Sep 28.

PMID:
27683822
50.

Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.

Nichols BE, Boucher CAB, van der Valk M, Rijnders BJA, van de Vijver DAMC.

Lancet Infect Dis. 2016 Dec;16(12):1423-1429. doi: 10.1016/S1473-3099(16)30311-5. Epub 2016 Sep 22.

PMID:
27665989

Supplemental Content

Loading ...
Support Center